Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability | Zendy

Gerard A. Rodrigues | Zendy; Matthew D. Mason | Zendy; LoriAnn Christie | Zendy; Candice Hansen | Zendy; Lisa M. Hernández | Zendy; James A. Burke | Zendy; Keith A. Luhrs | Zendy; Thomas C. Hohman | Zendy

Open Access

Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability

Author(s) -

Gerard A. Rodrigues,

Matthew D. Mason,

LoriAnn Christie,

Candice Hansen,

Lisa M. Hernández,

James A. Burke,

Keith A. Luhrs,

Thomas C. Hohman

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-25307

Subject(s) - vascular endothelial growth factor , angiogenesis , in vivo , neovascularization , pharmacology , vascular endothelial growth factor a , ranibizumab , vascular permeability , medicine , chemistry , cancer research , biology , bevacizumab , pathology , vegf receptors , microbiology and biotechnology , chemotherapy

DARPin molecules are a novel class of small proteins that contain engineered ankyrin repeat domain(s) and bind to target proteins with high specificity and affinity. Abicipar-pegol (abicipar), a DARPin molecule targeting vascular endothelial growth factor-A (VEGF-A), is currently under evaluation in patients with age-related macular degeneration. The pharmacodynamic properties of abicipar were characterized using in vivo and in vitro assays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research